Latest period
$576.00M
YoY change
+7.6%
5Y CAGR
-2.8%
Peak year (2018)
$924.00M
Cumulative CapEx
$9.69B
CapEx history chart for Gilead Sciences (GILD) from 1990 to 2025
Latest: $563.00M
CapEx growth chart for Gilead Sciences (GILD) from 1990 to 2025
Latest: +7.6%
CapEx history table for Gilead Sciences (GILD) from 1990 to 2025
| 2025 | $563.00M | +7.6% | +$40.00M | ||
| 2024 | $523.00M | -10.6% | −$62.00M | ||
| 2023 | $585.00M | -19.6% | −$143.00M | ||
| 2022 | $728.00M | +25.7% | +$149.00M | ||
| 2021 | $579.00M | -10.9% | −$71.00M | ||
| 2020 | $650.00M | -21.2% | −$175.00M | ||
| 2019 | $825.00M | -10.7% | −$99.00M | ||
| 2018 | $924.00M | +56.6% | +$334.00M | ||
| 2017 | $590.00M | -21.1% | −$158.00M | ||
| 2016 | $748.00M | +0.1% | +$1.00M | ||
| 2015 | $747.00M | +34.1% | +$190.00M | ||
| 2014 | $557.00M | +193.2% | +$367.00M | ||
| 2013 | $190.00M | -52.1% | −$207.00M | ||
| 2012 | $397.00M | +201.0% | +$265.10M | ||
| 2011 | $131.90M | +113.1% | +$70.02M | ||
| 2010 | $61.88M | -73.1% | −$168.17M | ||
| 2009 | $230.06M | +100.0% | +$115.05M | ||
| 2008 | $115.00M | +46.2% | +$36.36M | ||
| 2007 | $78.65M | -25.2% | −$26.56M | ||
| 2006 | $105.21M | +119.4% | +$57.26M | ||
| 2005 | $47.95M | -6.6% | −$3.42M | ||
| 2004 | $51.37M | +33.0% | +$12.76M | ||
| 2003 | $38.61M | +119.4% | +$21.01M | ||
| 2002 | $17.60M | -33.2% | −$8.73M | ||
| 2001 | $26.33M | +68.6% | +$10.71M | ||
| 2000 | $15.62M | +25.0% | +$3.12M | ||
| 1999 | $12.50M | +13.6% | +$1.50M | ||
| 1998 | $11.00M | -20.3% | −$2.80M | ||
| 1997 | $13.80M | +273.0% | +$10.10M | ||
| 1996 | $3.70M | +516.7% | +$3.10M | ||
| 1995 | $600.00K | -84.6% | −$3.30M | ||
| 1994 | $3.90M | — | — | ||
| 1992 | $4.40M | +780.0% | +$3.90M | ||
| 1991 | $500.00K | +66.7% | +$200.00K | ||
| 1990 | $300.00K | — | — |
- 2025$563.00M+7.6%
- 2024$523.00M-10.6%
- 2023$585.00M-19.6%
- 2022$728.00M+25.7%
- 2021$579.00M-10.9%
- 2020$650.00M-21.2%
- 2019$825.00M-10.7%
- 2018$924.00M+56.6%
- 2017$590.00M-21.1%
- 2016$748.00M+0.1%
- 2015$747.00M+34.1%
- 2014$557.00M+193.2%
- 2013$190.00M-52.1%
- 2012$397.00M+201.0%
- 2011$131.90M+113.1%
- 2010$61.88M-73.1%
- 2009$230.06M+100.0%
- 2008$115.00M+46.2%
- 2007$78.65M-25.2%
- 2006$105.21M+119.4%
- 2005$47.95M-6.6%
- 2004$51.37M+33.0%
- 2003$38.61M+119.4%
- 2002$17.60M-33.2%
- 2001$26.33M+68.6%
- 2000$15.62M+25.0%
- 1999$12.50M+13.6%
- 1998$11.00M-20.3%
- 1997$13.80M+273.0%
- 1996$3.70M+516.7%
- 1995$600.00K-84.6%
- 1994$3.90M—
- 1992$4.40M+780.0%
- 1991$500.00K+66.7%
- 1990$300.00K—
CapEx values are taken from Gilead Sciences's reported cash flow statements (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About CapEx at Gilead Sciences (GILD)
According to Gilead Sciences's latest reported financial statements, the company's current CapEx (TTM) is $576.00M. Capital expenditures (CapEx) are cash outlays for property, plant, and equipment and other long-lived productive assets — reported on the cash flow statement under investing activities. CapEx funds future capacity (factories, data centers, software, machinery), so rising spend can signal investment in growth, while heavy CapEx reduces free cash flow available to shareholders. We display CapEx as a positive amount (the absolute cash outflow); compare with revenue to gauge capital intensity and with total assets for the asset-base context.
Headline TTM above sums the four reported quarters through (reported ). Chart and table below cover the full reported history back to .
In 2025, Gilead Sciences (GILD) CapEx totalled $563.00M – grew 7.6% year-over-year.
Gilead Sciences CapEx has contracted on net over the period, with a -2.8% compound annual growth rate over 2020–2025 (5 years).
Gilead Sciences CapEx peaked at $924.00M in 2018; the latest annual figure is $563.00M in 2025 (39.1% below peak).
2018 marks the peak CapEx at $924.00M, with the historical low of $300.00K recorded in 1990.
Gilead Sciences Capital Expenditures by Year
Gilead Sciences Capital Expenditures 2025: $563.00M
In 2025, Gilead Sciences reported CapEx of $563.00M, grew 7.6% from 2024.
Gilead Sciences Capital Expenditures 2024: $523.00M
Gilead Sciences CapEx in 2024 was $523.00M, declined 10.6% below 2023.
Gilead Sciences Capital Expenditures 2023: $585.00M
2023's CapEx for Gilead Sciences came in at $585.00M, declined 19.6% below 2022.
Gilead Sciences Capital Expenditures 2022: $728.00M
Gilead Sciences posted CapEx of $728.00M in 2022, grew 25.7% from 2021.
Gilead Sciences Capital Expenditures 2021: $579.00M
Gilead Sciences CapEx in 2021 was $579.00M.
See more financial history for Gilead Sciences (GILD).
Sector peers by CapEx
Healthcare peers of Gilead Sciences (GILD), ranked by their latest CapEx
| $14.05B | |
| $7.84B | |
| $4.83B | |
| $4.11B | |
| $3.62B | |
| $2.81B | |
| $1.86B | |
| $1.21B |
- $14.05B
- $7.84B
- $4.83B
- $4.11B
- $3.62B
- $2.81B
- $1.86B
- $1.21B
Frequently asked questions
Gilead Sciences (GILD) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation